{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:08:13Z","timestamp":1775567293661,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Management Research Project of Shanghai Hospital Association","award":["Q2025032"],"award-info":[{"award-number":["Q2025032"]}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82373402, 82172925"],"award-info":[{"award-number":["82373402, 82172925"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai ShenKang Research Physicians Innovation and Transformation Ability Training Project","award":["SHDC2022CRT001"],"award-info":[{"award-number":["SHDC2022CRT001"]}]},{"name":"the Disciplinary Platform Development Fund of Fudan Zhongshan Cancer Prevention and Treatment Center","award":["2024KYPT18"],"award-info":[{"award-number":["2024KYPT18"]}]},{"name":"Policy Research Project of Shanghai Municipal Administration of Disease Prevention and Control","award":["2025JZ33"],"award-info":[{"award-number":["2025JZ33"]}]},{"name":"the Disciplinary Platform Construction Fund of Fudan Zhongshan Hospital Affiliated to Fudan University","award":["2025XKPT18"],"award-info":[{"award-number":["2025XKPT18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15801-0","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:06:50Z","timestamp":1772179610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies"],"prefix":"10.1186","volume":"26","author":[{"given":"Jing","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyou","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"2","key":"15801_CR1","first-page":"219","volume":"9","author":"X Ding","year":"2019","unstructured":"Ding X, Zhang WH, Li S, Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019;9(2):219\u201327.","journal-title":"Am J Cancer Res"},{"key":"15801_CR2","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70:102536.","journal-title":"EClinicalMedicine"},{"issue":"36","key":"15801_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"12","key":"15801_CR4","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"4","key":"15801_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"key":"15801_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"PF Wang","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730.","journal-title":"Front Pharmacol"},{"issue":"11","key":"15801_CR7","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/bcp.16184","volume":"90","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Lv M, Jin Z, Wu Y, Li X, Zhang N. Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study. Br J Clin Pharmacol. 2024;90(11):2870\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"15801_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15801_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology. 2020;72(1):315\u201329.","journal-title":"Hepatology"},{"key":"15801_CR10","first-page":"100978","volume":"44","author":"I Cherradi","year":"2025","unstructured":"Cherradi I, Ichou M, Houssaini MS, Ismaili N. Management of immune-related adverse events under PD-1\/PD-L1 inhibitors: Insights from a Moroccan real-world experience. Cancer Treat Res Commun. 2025;44:100978.","journal-title":"Cancer Treat Res Commun"},{"issue":"14","key":"15801_CR11","doi-asserted-by":"publisher","first-page":"e2414923","DOI":"10.1002\/advs.202414923","volume":"12","author":"H Yan","year":"2025","unstructured":"Yan H, Huang X, Zhou Y, Mu Y, Zhang S, Cao Y, et al. Disturbing Cholesterol\/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity. Adv Sci (Weinh). 2025;12(14):e2414923.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"15801_CR12","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1038\/s41598-023-34137-4","volume":"13","author":"X Jia","year":"2023","unstructured":"Jia X, Zhang X, Yan M, Sun D, Li R, Yang N, et al. Increased TG to HDL-C ratio is associated with severity of drug-induced liver injury. Sci Rep. 2023;13(1):6897.","journal-title":"Sci Rep"},{"issue":"7744","key":"15801_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41586-019-0904-1","volume":"566","author":"K Vriens","year":"2019","unstructured":"Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566(7744):403\u20136.","journal-title":"Nature"},{"key":"15801_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-981-33-6785-2_6","volume":"1316","author":"Y Xiang","year":"2021","unstructured":"Xiang Y, Miao H. Lipid Metabolism in Tumor-Associated Macrophages. Adv Exp Med Biol. 2021;1316:87\u2013101.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"15801_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00262-024-03748-9","volume":"73","author":"Q Xie","year":"2024","unstructured":"Xie Q, Zeng Y, Zhang X, Yu F. The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma. Cancer Immunol Immunother. 2024;73(9):171.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"15801_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","volume":"22","author":"X Qiao","year":"2023","unstructured":"Qiao X, Hu Z, Xiong F, Yang Y, Peng C, Wang D, et al. Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids Health Dis. 2023;22(1):45.","journal-title":"Lipids Health Dis"},{"issue":"20","key":"15801_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41388-024-03012-5","volume":"43","author":"Y Dong","year":"2024","unstructured":"Dong Y, Hu K, Zhang J, Zhu M, Liu M, Yuan Y, et al. ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases. Oncogene. 2024;43(20):1549\u201364.","journal-title":"Oncogene"},{"key":"15801_CR18","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"key":"15801_CR19","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute, Natl Inst Health; 2017."},{"key":"15801_CR20","doi-asserted-by":"crossref","unstructured":"Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015;17(1):14.","DOI":"10.3390\/ijms17010014"},{"issue":"3","key":"15801_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES. Drug-Induced Liver Injury - Types and Phenotypes. N Engl J Med. 2019;381(3):264\u201373.","journal-title":"N Engl J Med"},{"issue":"5","key":"15801_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021;116(5):878\u201398.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"15801_CR23","doi-asserted-by":"publisher","first-page":"e000366","DOI":"10.1136\/bmjmed-2022-000366","volume":"2","author":"T Gaster","year":"2023","unstructured":"Gaster T, Eggertsen CM, St\u00f8vring H, Ehrenstein V, Petersen I. Quantifying the impact of unmeasured confounding in observational studies with the E value. BMJ Med. 2023;2(1):e000366.","journal-title":"BMJ Med"},{"issue":"19","key":"15801_CR24","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1002\/cam4.3378","volume":"9","author":"SL Chan","year":"2020","unstructured":"Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, et al. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med. 2020;9(19):7052\u201361.","journal-title":"Cancer Med"},{"key":"15801_CR25","doi-asserted-by":"crossref","unstructured":"Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines. 2021;9(2):101.","DOI":"10.3390\/biomedicines9020101"},{"key":"15801_CR26","doi-asserted-by":"crossref","unstructured":"Wu MM, Yang YC, Hu ZQ, Chang JY, Xiao H, Miao C, et al. Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade. Cell Metab. 2026;38(1):208\u201327.e12.","DOI":"10.1016\/j.cmet.2025.11.009"},{"issue":"1","key":"15801_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","volume":"75","author":"CLC Gudd","year":"2021","unstructured":"Gudd CLC, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, et al. Activation and transcriptional profile of monocytes and CD8(+) T cells are altered in checkpoint inhibitor-related hepatitis. J Hepatol. 2021;75(1):177\u201389.","journal-title":"J Hepatol"},{"issue":"2","key":"15801_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.immuni.2009.11.014","volume":"32","author":"J-H Cho","year":"2010","unstructured":"Cho J-H, Kim H-O, Surh CD, Sprent J. T cell receptor-dependent regulation of lipid rafts controls naive CD8\u2009+\u2009T cell homeostasis. Immunity. 2010;32(2):214\u201326.","journal-title":"Immunity"},{"issue":"2","key":"15801_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrm2336","volume":"9","author":"E Ikonen","year":"2008","unstructured":"Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9(2):125\u201338.","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15801-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:35:10Z","timestamp":1775565310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15801"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15801-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the Declaration of Helsinki and approved by the Research Ethics Committee of Zhongshan Hospital (Approval No. B2022-509). Informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"442"}}